Amgen's promising PCSK9 candidate cleared another Phase III hurdle, this time in statin-intolerant patients, as the company piles up positive data with hopes of taking the lion's share of what could be a multibillion-dollar market.
Pfizer posted some promising top-line results for a Phase III pain drug, an abuse-resistant formulation of oxycodone that sounds quite a bit like Remoxy, the long-delayed treatment codeveloped with Pain Therapeutics.
Big Pharma never lost the black eye it earned over the years for neglecting the diseases of poor countries as the industry catered largely to the needs of the developed world. But some of its biggest players are trying.
While the death toll from Middle East respiratory syndrome coronavirus is now into the 70s, the situation is better than some feared, with the Hajj pilgrimage passing without incident. Drug combinations have had limited success against the virus though, prompting researchers to push ahead with development of vaccines.
A series of setbacks has made things tough for Merck KGaA's drug development operation, but CEO Karl-Ludwig Kley said the German company remains committed to the long-term promise of its pharma wing.
After more than two years of work on a GLP-1-targeting diabetes drug, partners Boehringer Ingelheim and Zealand Pharma are planning to start over, hitting the brakes on their program and looking to move on with a to-be-determined new compound.
Researchers have found that gravity and electrostatics are two important factors at play between cell membranes and drug reservoirs. With these new findings, the scientists hope to create systems that deliver cancer drugs slowly and continuously.
Covidien said it will abandon a renal denervation development program due to slower-than-expected market growth for the hypertension treatment. It's yet another industry setback for a medical device concept that only weeks ago was still generating enormous enthusiasm and expectations in the U.S.
The ongoing reorganization of Novartis has hit home in Basel. The pharma giant spread the word in Switzerland today that it is cutting about 500 positions while it amps up research staffing for cancer drug development and manufacturing as the company sets the stage for new product launches.
Roche's attempt to carve out a meaningful market in neurosciences has suffered a serious setback. The pharma giant says that bitopertin (once dubbed RG1678), failed the first two of 6 Phase III studies, raising some serious doubts about a new therapy designed to address common symptoms of schizophrenia.